- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MABWELL SHANGHAI BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 17.09. | MABWELL-B (02493): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 17.09. | MABWELL-B (02493): (1) POLL RESULTS OF THE 2026 FOURTH EXTRAORDINARY GENERAL MEETING; AND (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION | - | HKEx | ||
| 04.09. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT REGARDING POSTER PRESENTATIONS OF UPDATED CLINICAL DATA FOR 9MW1911 AT THE EUROPEAN RESPIRATORY SOCIETY (ERS) ... | 1 | HKEx | ||
| 04.09. | MABWELL-B (02493): 2026 INTERIM REPORT | 3 | HKEx | ||
| 19.08. | MABWELL-B (02493): DATE OF BOARD MEETING | - | HKEx | ||
| 31.07. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT ANNOUNCEMENT IN RELATION TO CLINICAL TRIAL APPLICATION FOR 9MW5211 INJECTION APPROVED BY NMPA | - | HKEx | ||
| 15.07. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT ANNOUNCEMENT IN RELATION TO CLINICAL TRIAL APPLICATION FOR 9MW5211 INJECTION APPROVED BY NMPA | - | HKEx | ||
| 07.07. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT ANNOUNCEMENT IN RELATION TO CLINICAL TRIAL APPLICATION FOR 9MW5211 INJECTION APPROVED BY NMPA | - | HKEx | ||
| 24.06. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT IN RELATION TO CLINICAL TRIAL APPLICATION FOR 9MW5211 INJECTION APPROVED BY NMPA | - | HKEx | ||
| 23.06. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT REGARDING THE RECEIPT OF NMPA APPROVAL FOR THE CLINICAL TRIAL APPLICATION OF 6MW5311 FOR INJECTION | - | HKEx | ||
| 18.06. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT REGARDING THE ORAL AND POSTER PRESENTATIONS OF THE LATEST CLINICAL DATA OF 9MW2821 AT THE 2026 ESMO CONGRESS ... | 1 | HKEx | ||
| 18.06. | MABWELL-B (02493): APPOINTMENT OF MEMBERS OF SENIOR MANAGEMENT | 1 | HKEx | ||
| 18.06. | MABWELL-B (02493): CHANGE OF AUTHORISED REPRESENTATIVE | - | HKEx | ||
| 18.06. | MABWELL-B (02493): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 18.06. | MABWELL-B (02493): ELECTION OF EMPLOYEE REPRESENTATIVE DIRECTOR | - | HKEx | ||
| 18.06. | MABWELL-B (02493): RETIREMENT OF DIRECTORS ELECTION OF THE THIRD SESSION OF THE BOARD OF DIRECTORS ELECTION OF CHAIRMAN OF THE THIRD SESSION OF THE BOARD ... | 1 | HKEx | ||
| 18.06. | MABWELL-B (02493): POLL RESULTS OF THE 2026 THIRD EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 12.06. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT REGARDING THE RECEIPT OF FDA CLEARANCE FOR THE CLINICAL TRIAL APPLICATION OF 6MW5311 FOR INJECTION | - | HKEx | ||
| 04.06. | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT IN RELATION TO CLINICAL TRIAL APPLICATION FOR 9MW5211 INJECTION APPROVED BY NMPA | 3 | HKEx | ||
| 01.06. | MABWELL-B (02493): POLL RESULTS OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING | - | HKEx |
1 2 3 Weiter >>
56 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ERASCA | 15,460 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| TANGO THERAPEUTICS | 24,170 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| DISC MEDICINE | 60,48 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update | Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026Launched Expanded... ► Artikel lesen | |
| COGENT BIOSCIENCES | 29,780 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| DYNE THERAPEUTICS | 15,960 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen | |
| CONTINEUM THERAPEUTICS | 8,565 | 0,00 % | Why Is Contineum Therapeutics Stock Falling Monday? | ||
| RECURSION PHARMACEUTICALS | 4,005 | -0,12 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| MBX BIOSCIENCES | 52,02 | 0,00 % | Stifel raises MBX Biosciences price target to $84 on obesity drug data | ||
| IMMUNOVANT | 29,470 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,145 | +0,09 % | AstraZeneca and Daiichi Sankyo to collaborate with Summit Therapeutics | ||
| PRAXIS PRECISION MEDICINES | 251,25 | -0,05 % | Praxis Precision Medicine Q2 2026 Earnings Call Transcript | ||
| PARABILIS MEDICINES | 28,950 | 0,00 % | Parabilis Medicines, Inc.: Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates | Advanced zolucatetide across multiple Wnt/ß-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors Announced strategic research collaboration with... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 38,240 | 0,00 % | Harmony Biosciences Names Peter Anastasiou As President And CEO As Jeffrey Dayno Plans Retirement | ||
| VERADERMICS | 122,36 | +0,19 % | Biotech Stocks At 52-Week Highs - Pacira BioSciences +44% On Acquisition News; Veradermics +14%, Haemonetics +17%, Concentra Group, HealthStream | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on October 8, 2026, driven by catalysts such as reports of an upcoming acquisition or upcoming financial reports.Pacira... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 74,52 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved... ► Artikel lesen |
Das Unternehmen MABWELL SHANGHAI BIOSCIENCE CO LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MABWELL SHANGHAI BIOSCIENCE CO LTD finden Sie auf Wallstreet Online.